CARA Cara Therapeutics, Inc. revenue, earnings and financials
For the quarter ended June 30, 2026, Cara Therapeutics, Inc. reported revenue of n/a, net income of −$6.46M and diluted EPS of −$0.69; for the fiscal year ended December 2025 revenue was n/a.
CARA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$26.7M, net income −$18.2M (margin n/a), EPS −$3.26
- Fiscal year ended Dec 2024: revenue $7.14M, gross profit n/a, operating income −$28.1M, net income −$29.4M (margin -411.9%), EPS −$11.42
- Fiscal year ended Dec 2023: revenue $21.0M, gross profit n/a, operating income −$121M, net income −$11.9M (margin -56.5%), EPS −$26.26
- Fiscal year ended Dec 2022: revenue $41.9M, gross profit n/a, operating income −$87.5M, net income −$85.5M (margin -204.2%), EPS −$19.12
- Fiscal year ended Dec 2021: revenue $23.0M, gross profit n/a, operating income −$89.1M, net income −$88.4M (margin -384.1%), EPS −$1.74
CARA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$6.46M, EPS −$0.69
- Quarter ended Mar 31, 2026: revenue n/a, net income −$6.80M, EPS −$0.73
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$7.27M, EPS $2.05
- Quarter ended Sep 30, 2025: revenue n/a, net income −$5.53M, EPS −$0.59
- Quarter ended Jun 30, 2025: revenue n/a, net income $4.17M, EPS −$1.00
- Quarter ended Mar 31, 2025: revenue $2.57M (up 20.3% year over year), net income −$9.58M, EPS −$3.72
- Quarter ended Dec 31, 2024 (from the annual report): revenue $1.46M (down 51.6% year over year), net income −$12.7M, EPS $13.67
- Quarter ended Sep 30, 2024: revenue $2.56M (down 47.5% year over year), net income −$5.51M, EPS −$2.14
- Quarter ended Jun 30, 2024: revenue $991K (down 85.7% year over year), net income −$6.98M, EPS −$2.71
- Quarter ended Mar 31, 2024: revenue $2.14M (down 65.4% year over year), net income −$4.20M, EPS −$20.24
- Quarter ended Dec 31, 2023 (from the annual report): revenue $3.00M (down 7.9% year over year), net income $74.3M, EPS −$24.67
- Quarter ended Sep 30, 2023: revenue $4.87M (down 55.0% year over year), net income −$28.0M, EPS −$0.52
- Quarter ended Jun 30, 2023: revenue $6.93M (down 69.9% year over year), net income −$31.5M, EPS −$0.58
- Quarter ended Mar 31, 2023: revenue $6.17M (up 28.7% year over year), net income −$26.7M, EPS −$0.49
- Quarter ended Dec 31, 2022 (from the annual report): revenue $3.26M, net income −$30.3M, EPS −$18.09
- Quarter ended Sep 30, 2022: revenue $10.8M (down 46.7% year over year), net income −$23.2M, EPS −$0.43
- Quarter ended Jun 30, 2022: revenue $23.0M, net income −$4.21M, EPS −$0.08
- Quarter ended Mar 31, 2022: revenue $4.79M (up 147.5% year over year), net income −$27.7M, EPS −$0.52
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$33.4M, EPS −$0.64
- Quarter ended Sep 30, 2021: revenue $20.3M, net income −$1.01M, EPS −$0.02
CARA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$23.5M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow −$18.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$92.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$78.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$60.1M, share buybacks n/a
CARA balance sheet
- Jun 30, 2026: cash $15.8M, total assets $17.5M, total liabilities $9.14M, shareholders' equity $8.38M
- Mar 31, 2026: cash $19.9M, total assets $25.8M, total liabilities $11.3M, shareholders' equity $14.5M
- Dec 31, 2025: cash $20.7M, total assets $32.1M, total liabilities $11.1M, shareholders' equity $20.9M
- Sep 30, 2025: cash $21.4M, total assets $39.0M, total liabilities $11.2M, shareholders' equity $27.9M
- Jun 30, 2025: cash $20.6M, total assets $43.8M, total liabilities $10.8M, shareholders' equity $32.9M
- Mar 31, 2025: cash $34.2M, total assets $38.9M, total liabilities $47.0M, shareholders' equity −$101M
- Dec 31, 2024: cash $31.6M, total assets $35.2M, total liabilities $40.8M, shareholders' equity −$91.1M
- Sep 30, 2024: cash $37.1M, total assets $51.3M, total liabilities $50.6M, shareholders' equity −$78.5M
Is CARA profitable?
No. Cara Therapeutics, Inc. lost $26.1M over the last four quarters.
What is CARA's EPS?
Diluted earnings per share over the last four quarters were $0.04; −$0.69 in the latest quarter.